Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the stag domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/vhosts/siteapp.hu/omixon.siteapp.hu/wp-includes/functions.php on line 6121
Measuring donor-derived cell-free DNA in your laboratory using HoloGRAFT - Omixon | NGS for HLA

Wednesday, 17 May, 2023 | 11:00 AM EST / 17:00 PM CEST | For APAC Region 17:00 PM JST

MEASURING DONOR-DERIVED CELL-FREE DNA IN YOUR LABORATORY USING HoloGRAFT

Cell-free DNA (cfDNA) has become the best-studied biomarker for graft injury. In this webinar, you will learn the state-of-the-art understanding of the role of donor-derived cfDNA in post-transplant monitoring of graft injury and its potential clinical utility. We shall review the different technologies available for relative and absolute quantification of dd-cfDNA, and how these technological choices impact laboratory workflow, turnaround time, analytical performance. We discuss how different biofluid sample sources may give different insight into graft injury. We shall introduce HoloGRAFT, Omixon's proprietary cell-free DNA assay and compare its measurement principle with other alternatives. We present the available clinical data to support the performance of the test in kidney transplantation. The session is followed by live Q&A.

For CEST/EST time zone, please register here:
Register here (CEST/EST)

 

For JST time zone, please register here:
Register here (JST)

Our Presenter:

“You will learn the state-of-the-art understanding of the role of donor-derived cfDNA in post-transplant monitoring.”

Attila Bérces, PhD

Founder & CEO, Omixon Biocomputing Ltd.

Monitoring absolute quantity of donor derived cfDNA

 

The HoloGRAFT™ Screening Plates, Monitoring Assays and HoloGRAFT™ Software meet the needs of any research application that requires highly sensitive detection and quantification of graft-derived, cell-free DNA after organ transplantation. HoloGRAFT uses copy number variant markers, stretches of DNA inherited in zero, one or two-copy forms.

  Read more
  • Designed to measure absolute concentration of donor-derived cfDNA in your own laboratory
  • SW solution provides complete, streamlined workflow for assay set up, analysis and full graphic reporting of monitoring data
  • Able to distinguish the patient and donor DNA fragments
  • From DNA samples to results in 3 hours
  • Graft-informative markers selected to be absent in the patient DNA
  • Fast & simple with low hands-on time

READY TO STEP INTO THE NEXT LEVEL
OF HLA SEQUENCING?

Contact your local Omixon representative at sales@omixon.com and we will provide you all the necessary information.

Join our monthly newsletter to receive our product and technology updates.

https://omixon.siteapp.hu/contact/sign-up-for-newsletter/